Microsize today announced the launch of its business as an independent company to support solubility and bioavailability enhancement via particle reduction technologies including micronization. This announcement marks the completion of the previously announced intent to acquire the North American micronization business from Lonza in Quakertown PA, USA. Microsize is the largest micronization business of its kind in North America. It comprises three facilities with over 100,000 square

Read more...

MEI Pharma, Inc. , a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 65,000 shares of the company’s common stock to two new employees. The stock options were granted as a material inducement to each new employee accepting employment with MEI in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a $0.60 exercise price per share, which is equal to the cl

Read more...

Considering the emerging need for medicines for the paediatric segment in the country and taking its acquisition drive forward, JB Pharma has announced its 3rd acquisition of 4 brands in the calendar year in the paediatric segment – “Z&D”, “Pedicloryl”, “Pecef” and “Ezinapi” from Dr Reddy’s Laboratories. All four brands – “Z&D”, “Pedicloryl”, “Pecef” and “Ezinapi&rdquo

Read more...

MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, today announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. The partnership will provide access to data from patient populations in Asia that have historically been underrepresent

Read more...

Akebia Therapeutics®, Inc.  a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. (Otsuka). As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million. As a result of the termination of the agreements, Akebia is regaining the r

Read more...

TetraScience, the R&D Data Cloud company, announced today that Chemaxon, a leading web-based cheminformatics and bioinformatics software provider, has joined the Tetra Partner Network to help customers dramatically increase their capacity to find and synthesize chemical compounds with overall improved property profiles. "Chemaxon is an industry leader with flexible solutions that support computational chemistry," said Simon Meffan-Main, Ph.D., Vice President, Tetra Par

Read more...

Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been cleared by the US Food and Drug Administration (FDA) to enter a first-in-human (FIH) study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malign

Read more...

Domain Therapeutics, a biopharmaceutical company focusing on the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017. M1069 is an orally available small molecule antagonist of adenosine receptors disco

Read more...